Purpose: To retrospectively determine the optimal b-value(s) of diffusion-weighted imaging (DWI) associated with intermediate-high risk cancer in the peripheral zone (PZ) of the prostate. 
Diffusion weighted imaging (DWI) is an integral part of the prostate MP-MRI. [6] [7] [8] [9] [10] ADC maps derived from DWI have not only been shown to detect PCa but also ADC values correlate with the histologic grade of PCa. [10] [11] [12] [13] [14] However, lesions on ADC maps can be subtle and it has been observed that inclusion of high b value (HBV) DWI improves the conspicuity of PCa. [15] [16] [17] [18] [19] Thus, HBV-DWI has been added to the recommended repertoire of sequences obtained during MP-MRI of PCa. 6, 7 HBV-DWI detects the increased restriction of water in the PCa relative to normal tissue without any post processing. 8 In normal tissue, water diffuses freely with little or almost no MR signal in HBV-DWI. Conversely, PCa tissue has increased diffusion restriction leading to a hyperintense signal pattern on HBV-DWI. Therefore, HBV-DWI, in effect, suppresses background normal tissue while highlighting PCa, making it easier to detect. 20, 21 The recently published Prostate Imaging and Reporting and Data System (PIRADSv2) criteria, recommends use of acquired or computed HBV-DWI with b-values above 1400 s/mm 2 to improve the conspicuity of clinically significant cancers. 6, 7 Multiple studies have tested the diagnostic accuracy of HBV-DWI for the detection of PCa, 15, 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] however, there has been little agreement on the optimal b-value for HBV-DWI. 16, [20] [21] [22] [23] [24] [25] [26] Typically, the highest b-value used for HBV-DWI is 2000 s/mm 2 
Materials and Methods

Study Population
This retrospective, single-institution study was approved by the local institutional review board and was compliant with the Health Insurance Portability and Accountability Act. 
TRUS/MRI Fusion Biopsies and ROI Drawings
Lesions were identified prospectively on MP-MRI (triplane T2W MRI, ADC maps derived from axial DWI, b 5 2000 s/mm 2 DWI from axial HBV-DWI and raw DCE MRI) by the same two radiologists (B.T. with 9 years and P.L.C. with 15 years of experience in reading prostate MRI) in consensus using an in-house scoring system for all patients as part of standard clinical interpretation. 4 PI-RADSv2 was not available at the data acquisition phase of this study, therefore, it was not used. Fusion-guided biopsies were performed for all identified lesions along with standard 12 core systemic biopsy. Biopsies were performed on a commercial TRUS/MRI fusion guided biopsy system (UroNav, Invivo, Gainesville, FL), where these identified lesions marked on high resolution T2W axial MRI is registered in real time with TRUS imaging plane to guide and obtained the biopsies from the lesions identified on MP-MRI. All lesions that were identified histopathologically as PCa from targeted biopsies were contoured on a single slice of b 5 0 s/mm 2 DWI from mbDWI and on a single slice of the ADC map using an open source software (Medical Image Processing, Analysis, and Visualization [MIPAV]; National Institutes of Health, Bethesda MD) In addition, the entire PZ region was also contoured on the same slice where the targeted lesion(s) was/were identified ( Figure 1 ) for background signal measurement.
Image Analysis
MATLAB (The MathWorks, Inc., Natick, MA) was used to perform image and some statistical analysis. The contrast between PCa and normal PZ on the same section was computed for DWI images on multi b-value DWI, 3-b-value DWI, and ADC. The contrast was defined as,
where I c is the mean value over the PCa ROI and I b is the mean value over the background PZ tissue.
Statistical Analysis
Statistical analysis was performed using R (The R Project for Statistical Computing). Performance of contrast in ADC maps obtained using standard DWI and in acquired and computed DWI images from mbDWI was evaluated using the area the under the curve (AUC) of receiver operating characteristics (ROC) analysis. 31 Paired comparisons between the AUC were done using Delong method. 32, 33 p-values below 0.05 were considered statistically significant.
Results
The final study population of 39 patients had 53 cancers (n 5 19 However, the distinction between clinically insignificant (low risk) and clinically significant (intermediate-high risk) cancers was not made in these studies. This study differs from previous studies because it compares the ability of HBV-DWI to distinguish low from intermediate-high risk tumors. Patient selection for biopsy is an important consideration in reducing health care costs related to the use of MRI for PCa. By identifying patients with abnormal but low risk disease, some biopsies could be avoided or at least deferred. This study has several limitations. First, we used TRUS/MRI fusion guided biopsy as a validation method instead of radical prostatectomy. The advantage of doing this is that it allows a broader class of patients to be included in the study (i.e., active surveillance and radiation therapy candidates as well as surgical candidates). There is a chance that a tumor will be missed on MP-MRI or missed/ undersampled at biopsy because this study did not use whole-mount histopathology as the gold standard. However, TRUS/MRI fusion guidance has been proven highly A fourth limitation of this study included using the CAPRA method on a per lesion basis instead of on a per patient basis. The CAPRA scoring system is one of the very few available validated nomograms that can allow patients with secondary Gleason pattern 4 to be an active surveillance candidate. Using this system on a per patient basis would not contribute to our primary objective to find the best high b-value in the detection of high risk prostate cancer in the peripheral zone as the sample size would artificially dilute our lesion categorizations. Thus, using the CAPRA scoring system on a per lesion basis was useful as an extra step to biopsy confirmation. Finally, this is a retrospective study with a relatively limited patient/ lesion population size which could introduce a potential patient selection bias that would be less likely to occur prospectively. However, the patients in this study were consecutive reducing the likelihood of a specific selection bias.
In conclusion, our study shows that b 5 1600 s/mm 
